Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 21.48 USD 1.7% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Catalyst Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one CPRX stock under the Base Case scenario is 19.8 USD. Compared to the current market price of 21.48 USD, Catalyst Pharmaceuticals Inc is Overvalued by 8%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CPRX Intrinsic Value
19.8 USD
Overvaluation 8%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Catalyst Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CPRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CPRX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Catalyst Pharmaceuticals Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Catalyst Pharmaceuticals Inc

Provide an overview of the primary business activities
of Catalyst Pharmaceuticals Inc.

What unique competitive advantages
does Catalyst Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Catalyst Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Catalyst Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Catalyst Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Catalyst Pharmaceuticals Inc.

Provide P/S
for Catalyst Pharmaceuticals Inc.

Provide P/E
for Catalyst Pharmaceuticals Inc.

Provide P/OCF
for Catalyst Pharmaceuticals Inc.

Provide P/FCFE
for Catalyst Pharmaceuticals Inc.

Provide P/B
for Catalyst Pharmaceuticals Inc.

Provide EV/S
for Catalyst Pharmaceuticals Inc.

Provide EV/GP
for Catalyst Pharmaceuticals Inc.

Provide EV/EBITDA
for Catalyst Pharmaceuticals Inc.

Provide EV/EBIT
for Catalyst Pharmaceuticals Inc.

Provide EV/OCF
for Catalyst Pharmaceuticals Inc.

Provide EV/FCFF
for Catalyst Pharmaceuticals Inc.

Provide EV/IC
for Catalyst Pharmaceuticals Inc.

Show me price targets
for Catalyst Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Catalyst Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Catalyst Pharmaceuticals Inc?

What are the Net Income projections
for Catalyst Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Catalyst Pharmaceuticals Inc?

What are the EPS projections
for Catalyst Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Catalyst Pharmaceuticals Inc?

What are the EBIT projections
for Catalyst Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Catalyst Pharmaceuticals Inc?

Compare the revenue forecasts
for Catalyst Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Catalyst Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Catalyst Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Catalyst Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Catalyst Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Catalyst Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Catalyst Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Catalyst Pharmaceuticals Inc.

Provide ROE
for Catalyst Pharmaceuticals Inc.

Provide ROA
for Catalyst Pharmaceuticals Inc.

Provide ROIC
for Catalyst Pharmaceuticals Inc.

Provide ROCE
for Catalyst Pharmaceuticals Inc.

Provide Gross Margin
for Catalyst Pharmaceuticals Inc.

Provide Operating Margin
for Catalyst Pharmaceuticals Inc.

Provide Net Margin
for Catalyst Pharmaceuticals Inc.

Provide FCF Margin
for Catalyst Pharmaceuticals Inc.

Show all solvency ratios
for Catalyst Pharmaceuticals Inc.

Provide D/E Ratio
for Catalyst Pharmaceuticals Inc.

Provide D/A Ratio
for Catalyst Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Catalyst Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Catalyst Pharmaceuticals Inc.

Provide Quick Ratio
for Catalyst Pharmaceuticals Inc.

Provide Current Ratio
for Catalyst Pharmaceuticals Inc.

Provide Cash Ratio
for Catalyst Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Catalyst Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Catalyst Pharmaceuticals Inc?

What is the current Free Cash Flow
of Catalyst Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Catalyst Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Catalyst Pharmaceuticals Inc

Current Assets 474.4m
Cash & Short-Term Investments 375.7m
Receivables 57.2m
Other Current Assets 41.6m
Non-Current Assets 231.9m
Long-Term Investments 13.1m
PP&E 3.6m
Intangibles 175.4m
Other Non-Current Assets 39.9m
Current Liabilities 92.3m
Accounts Payable 7.1m
Accrued Liabilities 72.9m
Other Current Liabilities 12.3m
Non-Current Liabilities 5.4m
Other Non-Current Liabilities 5.4m
Efficiency

Earnings Waterfall
Catalyst Pharmaceuticals Inc

Revenue
434.5m USD
Cost of Revenue
-57.9m USD
Gross Profit
376.6m USD
Operating Expenses
-290.7m USD
Operating Income
85.9m USD
Other Expenses
-17.8m USD
Net Income
68.1m USD

Free Cash Flow Analysis
Catalyst Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CPRX Profitability Score
Profitability Due Diligence

Catalyst Pharmaceuticals Inc's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Exceptional 3-Years Revenue Growth
Positive Gross Profit
78/100
Profitability
Score

Catalyst Pharmaceuticals Inc's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

CPRX Solvency Score
Solvency Due Diligence

Catalyst Pharmaceuticals Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
93/100
Solvency
Score

Catalyst Pharmaceuticals Inc's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CPRX Price Targets Summary
Catalyst Pharmaceuticals Inc

Wall Street analysts forecast CPRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CPRX is 32.49 USD with a low forecast of 28.28 USD and a high forecast of 39.9 USD.

Lowest
Price Target
28.28 USD
32% Upside
Average
Price Target
32.49 USD
51% Upside
Highest
Price Target
39.9 USD
86% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CPRX?

Click here to dive deeper.

Dividends

Catalyst Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CPRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CPRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

CPRX News

Other Videos

Profile

Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.5B USD

Dividend Yield

0%

Description

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company is headquartered in Coral Gables, Florida and currently employs 76 full-time employees. The company went IPO on 2006-11-08. The firm is focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. The firm operates through the development and commercialization of drug products. The firm is developing a pipeline of medicines for other rare diseases. The firm's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse contains the phosphate salt of amifampridine. The firm's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Its wholly owned subsidiary is Catalyst Pharmaceuticals Ireland, Ltd.

Contact

FLORIDA
Coral Gables
355 Alhambra Circle, Suite 801
+13055292522.0
catalystpharma.com

IPO

2006-11-08

Employees

76

Officers

President, CEO & Director
Mr. Richard John Daly M.B.A.
Executive VP, COO & Chief Scientific Officer
Dr. Steven R. Miller Ph.D.
Chief Medical & Regulatory Officer
Dr. Gary Ingenito M.D., Ph.D.
Executive VP & Chief Commercial Officer
Mr. Jeffrey Del Carmen
Executive VP, Treasurer & CFO
Mr. Michael W. Kalb CPA
VP & Head of Investor Relations
Ms. Mary Coleman
Show More
Chief Compliance Officer & Chief Legal Officer
Mr. Brian Elsbernd J.D.
Vice President of Sales
Mr. Pete Curry Sr.
Senior Vice President of Medical Affairs & Drug Discovery
Dr. Stanley Iyadurai M.D., Ph.D.
Chief Strategy Officer
Dr. Preethi Sundaram Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one CPRX stock?

The intrinsic value of one CPRX stock under the Base Case scenario is 19.8 USD.

Is CPRX stock undervalued or overvalued?

Compared to the current market price of 21.48 USD, Catalyst Pharmaceuticals Inc is Overvalued by 8%.

Back to Top